Oncolytics Biotech regains compliance with NASDAQ minimum bid price rule

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) received formal notification from NASDAQ on July 22, 2025, that it has regained compliance with the exchange's minimum bid price requirement, according to a company statement.

The clinical-stage biotechnology company was previously notified by NASDAQ on February 13, 2025, that its common shares had failed to maintain the required minimum bid price of $1.00 over 30 consecutive business days. The company has now satisfied the compliance requirement by maintaining a closing bid price at or above $1.00 per share for 10 consecutive business days from July 8 through July 21, 2025.

The company's common shares will continue trading on the NASDAQ Capital Market under the ticker "ONCY." NASDAQ has closed the matter and confirmed that Oncolytics is now in compliance with all listing standards.

Oncolytics develops pelareorep, an immunotherapeutic agent delivered intravenously for cancer treatment. The company is conducting combination clinical trials in solid malignancies and advancing toward registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA.

You May Also Be Interested In

• Arcutis launches virtual platform linking patients to dermatologists
• Alkami's MANTL unit crosses $40B in deposits, 1M hours saved
• CME Group plans beef trim futures launch for July 2026